tiprankstipranks
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market
IPHA
Innate Pharma
RESEARCH TOOLSreports
Want to see IPHA full AI Analyst Report?

Innate Pharma (IPHA) Income Statement

132 Followers

Innate Pharma Income Statement

Last quarter (Q4 2025), Innate Pharma's total revenue was €-2.07M, a decrease of -112.52% from the same quarter last year. In Q4, Innate Pharma's net income was €-27.63M. See Innate Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
€ 2.79M€ 12.62M€ 51.90M€ 57.67M€ 12.11M
Gross Profit
€ 2.79M€ 12.62M€ 5.62M€ 6.01M€ -22.30M
Operating Expenses
€ 56.21M€ 64.20M€ 18.29M€ 63.44M€ 25.52M
Depreciation and Amortization
€ 5.09M€ 1.99M€ 5.09M€ 45.41M€ 4.60M
EBITDA
€ -43.65M€ -46.91M€ -1.84M€ -12.28M€ -43.23M
Operating Income
€ -53.42M€ -51.58M€ -12.67M€ -57.42M€ -47.83M
Other Income/Expenses
€ 4.25M€ 2.10M€ 5.10M€ -547.00K€ 2.35M
Pretax Income
€ -49.18M€ -49.47M€ -7.57M€ -57.97M€ -45.48M
Net Income
€ -47.24M€ -49.47M€ -7.57M€ -58.10M€ -52.81M
Per Share Metrics
Basic EPS
€ -0.53€ -0.61€ -0.09€ -0.73€ -0.57
Diluted EPS
€ -0.53€ -0.61€ -0.09€ -0.73€ -0.57
Weighted Average Shares Outstanding
 89.42M 81.05M 84.11M 79.59M 79.54M
Weighted Average Shares Outstanding (Diluted)
 89.42M 81.05M 84.11M 79.64M 79.54M
Currency in EUR

Innate Pharma Earnings and Revenue History